GSK's TYKERB Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

GlaxoSmithKline announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB (lapatinib) as a first- line, all-oral treatment for women with metastatic breast cancer.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.